Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension

Fundamental and Clinical Pharmacology

Volumn 21, Issue 4, 2007, Pages 437-443

  Zateyshchikov, Dmitry A ^a   Minushkina, Larissa O ^a   Brovkin, Alexey N ^b   Savel'eva, Ekaterina G ^c   Zateyshchikova, Anna A ^c   Manchaeva, Baira B ^c   Nikitin, Alexey G ^b   Sidorenko, Boris A ^a   Nosikov, Valery V ^b  

^a Scientific Educational Medical Centre of General Management   (Russian Federation)

^b STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^c City Clinical Hospital N55   (Russian Federation)

Author keywords

Arg389Gly polymorphism of ADRB1 gene and Pro34Ser polymorphism of CYP2D6 gene; Betaxolol; Essential hypertension; Pharmacogenetics

Indexed keywords

ARGININE DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR; BETAXOLOL; CYTOCHROME P450 2D6; LOKREN; PROLINE DERIVATIVE; SERINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONOTROPISM; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG METABOLISM; DRUG RESPONSE; ESSENTIAL HYPERTENSION; EXERCISE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HEART RATE; HEREDITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MONOTHERAPY; NIGHT; PRIORITY JOURNAL; REST; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TIME;

ANTIHYPERTENSIVE AGENTS; BETAXOLOL; BLOOD PRESSURE; CYTOCHROME P-450 CYP2D6; EXERCISE TEST; FEMALE; GENE FREQUENCY; GENOTYPE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-1; REST;

EID: 34447558692     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00518.x     Document Type: Conference Paper

References (21)

1. Lopez-Sendon J., Swedberg K., McMurray J. et al. Expert consensus document on b-adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology. Eur. Heart J. (2004) 25 1341 1362.
2. Julius S., Alderman M.H., Beevers G. et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy. The LIFE study. J. Am. Coll. Cardiol. (2004) 43 1047 1055.
3. Irvine N.A., Lipworth B.J., McDevitt D.G. A dose-ranging study to evaluate the beta-adrenoreceptor selectivity of single doses of betaxolol. Br. J. Clin. Pharmacol. (1990) 30 119 126.
4. Suzuki J., Watanabe K., Tsuruokac T. Beneficial effects of betaxolol, a selective antagonist of beta-1adrenoreceptors, on exercise-induced myocardial ischemia in patients with coronary vasospasm. Int. J. Cardiol. (2003) 91 227 232.
5. Snow V., Weiss K.B., LeFevre M.L. et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann. Intern. Med. (2003) 139 1009 1017.
6. Figulla H.R., Krzeminska-Pakula M., Wrabec K. et al. Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). Int. J. Cardiol. (2006) 113 153 160.
7. Williams R.L., Goyle K.K., Herman T.S. et al. Dose-dependent effects of betaxolol in hypertension: a double-blind, multicenter study. J. Clin. Pharmacol. (1992) 32 360 367.
8. Chobanian A.V., Lenfont C., Jones D.W., Roccella E.J. The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The 1. JNC 7. Report. JAMA (2003) 289 2560 2572.
9. Maqbool A., Hall A.S., Ball S.G., Balmforth A.S. Common polymorphisms of b1-adrenoreceptor: identification and rapid screening assay. Lancet (1999) 353 897.
10. Mason D.A., Moore J.D., Green S. A., Liggett S.B. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J. Biol. Chem. (1999) 274 12670.
11. Nelson D.R., Koymans L., Kamataki T. et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics (1996) 6 1 42.
12. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. (2005) 5 6 13.
13. Wuttke H., Rau T., Heide R. et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin. Pharmacol. Ther. (2002) 72 429 437.
14. Huang J., Chuang S.K., Cheng C.L., Lai M.L. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin. Pharmacol. Ther. (1999) 65 402 407.
15. Wang S.L., Lai M.D., Huang J.D. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab. Dispos. (1999) 27 385 388.
16. Bruck H., Leineweber K., Temme T. et al. The Arg389Gly beta1-adrenoreceptor polymorphism and catecholamine effects on plasma-renin activity. J. Am. Coll. Cardiol. (2005) 46 2111 2115.
17. Nieminen T., Lehtimäki T., Laiho J. et al. Effects of polymorphisms in β1-adrenoreceptor and α-subunit of G protein on heart rate and blood pressure during exercise test. The Finnish Cardiovascular Study. J. Appl. Physiol. (2006) 100 507 511.
18. J ohnson J.A., Zineh I., Puckett B.J. et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. (2003) 74 44 52.
19. Schwartz S.G., Puckett B.J., Allen R.C. et al. Beta1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. Ophthalmology (2005) 112 2131 2136.
20. White H.L., de Boer R.A., Maqbool A. et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur. J. Heart Fail. (2003) 5 463 468.
21. Karlsson J., Lind L., Hallberg P. et al. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin. Cardiol. (2004) 27 347 350.